Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:25 PM
Ignite Modification Date:
2025-12-24 @ 7:25 PM
NCT ID:
NCT01110603
Eligibility Criteria:
Inclusion Criteria:
* Participant has a locally advanced or metastatic solid tumor for which carboplatin, carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin are the standard of care.
* Participant has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
Exclusion Criteria:
* Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks prior to entering the study.
* Participant has had more than two prior lines of chemotherapy.
* Participant has known central nervous system metastases or a primary central nervous system tumor.
* Participant is pregnant or breastfeeding or expecting to conceive during the timeframe of the study.
* Participant is known to be human immunodeficiency virus (HIV) positive.
* Participant has a history of Hepatitis B or C.
* Participant has a symptomatic pleural effusion.
* Participant with a left ventricular ejection fraction (LVEF) below the institutional norm, or with prior exposure to doxorubicin is not eligible for the MK4827 + carboplatin/liposomal doxorubicin study arm.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01110603
Study Brief:
Protocol Section:
NCT01110603